The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis (TB) remains a challenge for clinicians for several reasons, including the large number of drugs required, the cost, the tolerability of single drugs and their combinations, and the effectiveness and long treatment duration [1–6]. Therefore, fresh attention has recently been paid to new and repurposed anti-TB drugs [4, 5, 7–18]. Bedaquiline is well tolerated: evidence indicates a minority of patients discontinue use due to QT extension http://ow.ly/9NRT30fNv4y

中文翻译：

---

贝达喹啉的心脏安全性：对证据的系统和批判性分析

由于多种原因，多重耐药（MDR）或广泛耐药（XDR）结核病（TB）的治疗仍然是临床医生面临的挑战，包括所需的大量药物、成本、单一药物及其组合的耐受性，以及疗效和治疗持续时间长 [1-6]。因此，最近对新的和重新利用的抗结核药物给予了新的关注 [4, 5, 7-18]。贝达喹啉耐受性良好：证据表明少数患者因 QT 延长而停止使用 http://ow.ly/9NRT30fNv4y